Our study validates LHPP as a genuine suppressor of prostate cancer, with its deficiency linked to an unfavorable patient outcome, thereby positing therapeutic targeting of LHPP as a potential strategy to curb prostate cancer progression and dissemination. Here, LHPP is linked to prostate carcinoma.